Xiaoqiang Yan

This inventor holds 29 USPTO granted patents and 10 published patent applications, plus 9 CIPO patents and 13 EPO patents, primarily in Biopharmaceutical Development. Top assignees: Hutchison Medipharma Enterprises Limited, Generon (Shanghai) Corporation Ltd., Evive Biotechnology (Shanghai) Ltd. Active years: 2008-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiaoqiang Yan. Retrieved from https://idiyas.com/inventor/xiaoqiang-yan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 (Patent Applications = 10)

% Patents Active = 72.4

CIPO Patents = 9 (Patent Applications = 5)

EPO Patents = 13 (Patent Applications = 20)

Average Co-Inventor Count = 5.1

ph-index = 4

Forward Citations = 49(Granted Patents)

Location History:

Nan Hui, CN (2009 - 2013)
Shanghai, CN (2008 - 2023)

Company Filing History:

13 out of 15

Hutchison Medipharma Enterprises Limited

patents

8 out of 10

Generon (Shanghai) Corporation Ltd.

patents

4 out of 5

Evive Biotechnology (Shanghai) Ltd

patents

4. 2 out of 3

Nutrition Science Partners Limited

patents

5. 1 out of 37

Hutchison Medipharma Limited

University of Pittsburgh

patents

where one patent can have more than one assignee

Years Active: 2008-2026

Loading Chart...

Areas of Expertise:

Bispecific Antigen Binding Proteins

Interleukin-22

G-CSF Dimer

Quinazoline Compounds

Neurodegenerative Diseases

Graft Versus Host Disease

Pyrimidine Derivatives

Angiogenesis

Medicinal Applications

Intravenous Administration

Tumor Necrosis Factor

Viral Hepatitis

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12577305 - MULTISPECIFIC ANTIGEN BINDING PROTEINS CAPABLE OF BINDING CD19 AND CD3, AND USE THEREOF (2026-03-17),

2. 12527875 - METHODS FOR TREATING GRAFT VERSUS HOST DISEASE (2026-01-20),

3. 12460000 - Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof (2025-11-04),

4. 11654104 - Use of IL-22 dimer in manufacture of a medicament for intravenous administration (2023-05-23),

5. 11510966 - Use of IL-22 in treating necrotizing enterocolitis (2022-11-29),

6. 10870701 - Multispecific fab fusion proteins and use thereof (2020-12-22),

7. 10543169 - Use of IL-22 dimer in manufacture of a medicament for intravenous administration (2020-01-28),

8. 9642917 - Use of G-CSF dimer in preparation of medicament for treatment of neurodegenerative diseases (2017-05-09),

9. 9629898 - Use of interleukin-22 in treating viral hepatitis (2017-04-25),

10. 9352024 - Uses of interleukin-22(IL-22) in treating and preventing nerve damage diseases or neurodegenerative diseases (2016-05-31),

11. 9273108 - Recombinant human G-CSF dimer and use thereof for the treatment of neurological diseases (2016-03-01),

12. 9168253 - Quinazoline compounds (2015-10-27),

13. 8945528 - Use of interleukin-22 in treating viral hepatitis (2015-02-03),

14. 8901143 - Pyrimidine derivatives (2014-12-02),

15. 8557546 - Recombinant human G-CSF dimer and use thereof for the treatment of neurological diseases (2013-10-15),

Title: Innovations of Xiaoqiang Yan in Medical Research

Introduction

Xiaoqiang Yan is a prolific inventor based in Shanghai, China. With an impressive portfolio of 26 patents, he has made significant contributions to the field of medical research, particularly in the use of IL-22 for therapeutic purposes. His work not only underlines his expertise but also reflects his dedication to advancing medical science.

Latest Patents

Among his latest patents, two stand out due to their potential impact on treating severe medical conditions. The first patent focuses on the "Use of IL-22 dimer in manufacture of a medicament for intravenous administration." This application outlines methods for administering an IL-22 dimer, specifying effective dosages ranging from about 2 µg/kg to about 200 µg/kg. The patent emphasizes the importance of these methods in treating various diseases through intravenous administration.

The second patent's title, "Use of IL-22 in treating necrotizing enterocolitis," discusses innovative approaches for preventing and treating this serious intestinal inflammation. By utilizing IL-22, dimer, or multimer forms, his invention promises to offer significant therapeutic options for patients suffering from necrotizing enterocolitis and similar conditions.

Career Highlights

Xiaoqiang Yan has built a notable career in the medical and pharmaceutical industries. He has been associated with companies such as Hutchison Medipharma Enterprises Limited and Generon (Shanghai) Corporation Ltd., where he played vital roles in research and development. His work has consistently focused on harnessing biological compounds for innovative medical treatments.

Collaborations

Throughout his career, Xiaoqiang has collaborated with several distinguished colleagues, including Weihan Zhang and Jifeng Duan. These partnerships have contributed to the development of significant patents and have fostered a collaborative environment for exploring new medical innovations.

Conclusion

Xiaoqiang Yan's contributions to the field of medical science are profound, particularly through his work with IL-22. His patents pave the way for advancements in treating serious health issues, reflecting his role as a key innovator in the industry. As more researchers and companies harness his inventions, the potential for improved medical therapies continues to grow.

Profile summary based on public USPTO records.